| Literature DB >> 35054127 |
Tudor Lucian Pop1,2, Cornel Olimpiu Aldea3, Dan Delean3, Bogdan Bulata3, Dora Boghiţoiu4,5, Daniela Păcurar4,5, Coriolan Emil Ulmeanu4,5, Alina Grama1,2.
Abstract
OBJECTIVES: In children, acute liver failure (ALF) is a severe condition with high mortality. As some patients need liver transplantation (LT), it is essential to predict the fatal evolution and to refer them early for LT if needed. Our study aimed to evaluate the prognostic criteria and scores for assessing the outcome in children with ALF.Entities:
Keywords: King’s College Hospital criteria; acute liver failure; children; model for end-stage liver disorder; pediatric end-stage liver model; prognosis
Year: 2022 PMID: 35054127 PMCID: PMC8778932 DOI: 10.3390/jcm11020432
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Demographic data, clinical and laboratory parameters, and prognostic scores in children with ALF based on the disease outcome.
| Variable | Survivors with Native Liver under Medical Treatment | Poor Outcome | |
|---|---|---|---|
|
|
|
|
|
| Males ( | 45 (42.45%) | 28 (50.91%) | 0.30670 |
| AST (UI/L) | 1 332.02 ± 2 057.03 | 1 028.38 ± 1 779.19 | 0.354363 |
| ALT (UI/L) | 1 051.47 ± 1 305.89 | 699.35 ± 1 229.77 | 0.099954 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| White blood cells (/mm3) | 14 422 ± 21 178 | 14 126 ± 8 990 | 0.921381 |
| Platelets (/mm3) | 198 490 ± 106 904 | 207 418 ± 166 127 | 0.680128 |
| Ceruloplasmin (mg/dL) * | 10.175 ± 5.863 | 7.75 ± 4.179 | 0.52570 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Renal replacement ( | 11 (10.38%) | 10 (18.18%) | 0.16317 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LT—liver transplantation; AST—aspartate aminotransferase; ALT—alanine aminotransferase; TB—total bilirubin; DB—direct bilirubin; INR—International normalized ratio; PELD—Pediatric End-Stage Liver Disease; MELD—Model for End-Stage Liver Disease; MELD-Na—Model for End-Stage Liver Disease including sodium level; KCC—King’s College Criteria. Continuous parameters are represented as mean ± standard deviation and categorical parameters as number and percentage. * Serum level of ceruloplasmin was evaluated only for patients with Wilson’s Disease.
The PELD, MELD, MELD-Na scores function to the etiology of acute liver failure.
| Survivors with Native Liver under Medical Treatment | Poor Outcome | ||
|---|---|---|---|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
| PELD | 13.63 ± 7.80 | 15.52 ± 9.61 | 0.546069 |
| MELD | 17 ± 4.24 | 26 ± 0 | 0.333333 |
| MELD-Na | 21 ± 7.07 | 26 ± 0 | 0.666667 |
|
| |||
| PELD | 15.06 ± 6.12 | 14.50 ± 0 | 0.9333 |
| MELD | 23.50 ± 6.89 | ||
| MELD-Na | 24.17 ± 6.55 | ||
|
| |||
| IEM—PELD | 31.92 ± 14.06 | 25.90 ± 16.92 | 0.491631 |
| WD—MELD | 20 ± 0 | 45.80 ± 8.93 | 0.057692 |
|
|
|
|
|
|
| |||
|
|
|
|
|
| MELD | 21 ± 0 | 19 ± 0 | |
| MELD-Na | 24 ± 0 | 19 ± 0 | |
PELD—Pediatric End-Stage Liver Disease; MELD—Model for End-Stage Liver Disease; MELD-Na—Model for End-Stage Liver Disease including sodium level; LT—liver transplantation, IEM—inborn errors of metabolism; WD—Wilson’s disease.
Figure 1ROC curves in predicting the fatal outcome in ALF: teenagers (a), toxic causes (b), children up to 12 years old (c) and children from one to 12 years (infants and neonates excluded) (d). MELD— Model for End-Stage Liver Disease; MELD-Na—Model for End-Stage Liver Disease including sodium level; PELD—Pediatric End-Stage Liver Disease; INR—International Normalized Ratio; TB—total bilirubin.
Performances of MELD, MELD-Na, and PELD scores, INR, TB serum level, and KCC in predicting the fatal outcome in ALF.
| Parameter | Cut-Off | Sensitivity | Specificity | PPV | NPV | AUROC |
|---|---|---|---|---|---|---|
|
| ||||||
|
| 3 | 60% | 86.5% | 64.3% | 84.2% | 0.7946 |
|
| 2.3 mg/dL | 80% | 70.3% | 52.2% | 89.7% | 0.7991 |
|
| 28 | 73.3% | 81.1% | 61.1% | 88.2% | 0.8495 |
|
| 28 | 73.3% | 81.1% | 61.1% | 88.2% | 0.8576 |
|
| ||||||
|
| 2.5 | 85.7% | 64.3% | 37.5% | 94.7% | 0.7781 |
|
| 1.3 mg/dL | 100% | 64.3% | 41.2% | 100% | 0.8367 |
|
| 24 | 100% | 75% | 50% | 100% | 0.9056 |
|
| 26 | 100% | 75% | 50% | 100% | 0.9031 |
|
| ||||||
|
| 3 | 40% | 87% | 64% | 71.4% | 0.6045 |
|
| 3.4 mg/dL | 65% | 58% | 47.3% | 74.1% | 0.5725 |
|
| 18.9 | 60% | 75.4% | 58.5% | 76.5% | 0.6686 |
|
| ||||||
|
| 3 | 50% | 95.7% | 80% | 84.9% | 0.7334 |
|
| 4 mg/dL | 56.2% | 61.7% | 33.3% | 80.6% | 0.5286 |
|
| 19.5 | 62.5% | 85.1% | 58.8% | 87% | 0.7181 |
|
| ||||||
|
| 10 | 12.5% | 100% | 100% | 51.2% | 0.4896 |
|
| 6.6 mg/dL | 54.2% | 77.3% | 72.2% | 60.7% | 0.6146 |
|
| 12.9 | 75% | 40.9% | 58.1% | 60% | 0.5511 |
|
| ||||||
|
| ||||||
|
| 25.00% | 77.27% | 54.55% | 48.57% | 50% | |
|
| 18.75% | 97.87% | 75% | 77.97% | 77.78% | |
|
| 46.67% | 100% | 100% | 82.22% | 84.61% | |
|
| ||||||
|
| 36.36% | 100% | 100% | 88.33% | 89.06% | |
|
| 44.44% | 66.67% | 72.73% | 37.50% | 51.85% | |
|
| 0% | 88.46% | 0% | 60.53% | 56.10% | |
|
| 0% | 100% | 0% | 93.33% | 93.33% | |
|
| 40% | 100% | 100% | 40% | 57.14% | |
MELD—Model for End-Stage Liver Disease; MELD-Na—Model for End-Stage Liver Disease including sodium level; PELD—Pediatric End-Stage Liver Disease; INR—International Normalized Ratio; TB—total bilirubin; KKC—King’s College Criteria; PPV—positive predictive value; NPV—negative predictive value; AUROC—Area Under the Receiver Operating Characteristic.